Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

Summary

Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbation's caused by a multitude of organisms. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa. In acute CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CFMATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy.

Conditions

• Cystic Fibrosis

Interventions

DRUG

Ceftazidime

DRUG

Tobramycin

Sponsors & Collaborators

• Queen's University, Belfast

  collaborator OTHER

• University of Paris 5 - Rene Descartes

  collaborator OTHER

• University of Dundee

  collaborator OTHER

• University of Washington

  collaborator OTHER

• University Hospital Heidelberg

  collaborator OTHER

• Teagasc

  collaborator INDUSTRY

• Clininfo S.A.

  collaborator INDUSTRY

• GABO:mi

  collaborator INDUSTRY

• Papworth Hospital NHS Foundation Trust

  collaborator OTHER_GOV

• KU Leuven

  collaborator OTHER

• Assistance Publique - Hôpitaux de Paris

  collaborator OTHER

• European Union

  collaborator OTHER

• University College Cork

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Model

PARALLEL

Eligibility

Min Age

16 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-10-01

Primary Completion

2017-06-30

Completion

2018-06-30

Countries

• Ireland

Study Locations